Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
topic
Journal for ImmunoTherapy of Cancer
Journal for ImmunoTherapy of Cancer
281 Development of syngeneic mouse models to study the therapeutic efficacy of chimeric antigen receptor T cells against solid tumors
Ping-Hsien
Lee
,
Shannon
Breen
,
Ashley
Merlino
,
Lorenzo
Ortiz
,
Rosa
Carrasco
,
Gordon
Moody
,
Allison
Barrett
,
Letizia
Giardino
Journal for ImmunoTherapy of Cancer
Nov 2023,
11
(Suppl 1)
A322;
DOI:
10.1136/jitc-2023-SITC2023.0281
282 Dual antigen targeting CAR T cells armored with a dominant-negative TGF-β Receptor II enhance antitumor potency by overcoming TGF-β immunosuppression in GBM
Nannan
Li
,
Jesse
Rodriguez
,
Zev
Binder
,
Donald
O’Rourke
Journal for ImmunoTherapy of Cancer
Nov 2023,
11
(Suppl 1)
A323;
DOI:
10.1136/jitc-2023-SITC2023.0282
283 Preclinical development and characterization of allogeneic CAR T cells targeting Claudin18.2-positive tumors
Zhe
Li
,
Barbra
Sasu
,
Siler
Panowski
Journal for ImmunoTherapy of Cancer
Nov 2023,
11
(Suppl 1)
A324;
DOI:
10.1136/jitc-2023-SITC2023.0283
284 A novel hybrid T-cell receptor form of CAR-T cells showed enhanced activity against solid tumors
Meiou
Liu
,
Yasushi
Akahori
,
Hiroshi
Fujiwara
,
Yoshihiro
Miyahara
Journal for ImmunoTherapy of Cancer
Nov 2023,
11
(Suppl 1)
A325;
DOI:
10.1136/jitc-2023-SITC2023.0284
285 Proof-of-concept of a non-gene editing technology using shRNA down-regulation to engineer and optimize CAR T-cell functionality
Caroline
Lonez
,
Jennifer
Bolsee
,
Fanny
Huberty
,
Thuy
Nguyen
,
Celine
Jacques-Hespel
,
Benjamin
Demoulin
,
Anne
Flament
,
Eytan
Breman
Journal for ImmunoTherapy of Cancer
Nov 2023,
11
(Suppl 1)
A326;
DOI:
10.1136/jitc-2023-SITC2023.0285
286 Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity
Leyuan
Ma
Journal for ImmunoTherapy of Cancer
Nov 2023,
11
(Suppl 1)
A327-A328;
DOI:
10.1136/jitc-2023-SITC2023.0286
287 Identification of potentially safe and selective CAR targets for head and neck cancer via a pan-cancer single cell transcriptome analysis
Sanna
Madan
,
Eytan
Ruppin
Journal for ImmunoTherapy of Cancer
Nov 2023,
11
(Suppl 1)
A329;
DOI:
10.1136/jitc-2023-SITC2023.0287
289 Defining the T cell functional attributes of effective CAR T cell donors
Michaela
Meehl
,
Meghan W
Dukes
,
Giedre
Krenciute
Journal for ImmunoTherapy of Cancer
Nov 2023,
11
(Suppl 1)
A330;
DOI:
10.1136/jitc-2023-SITC2023.0289
290 IL-15 is required for optimal anti-tumor activity of Vγ9Vδ2 T cells against glioblastoma
Allyson E
Moore
,
Nickolas
Serniuck
,
Arya
Afsahi
,
Hayley
Nault
,
Sheila K
Singh
,
Jonathan L
Bramson
Journal for ImmunoTherapy of Cancer
Nov 2023,
11
(Suppl 1)
A331;
DOI:
10.1136/jitc-2023-SITC2023.0290
291 Time-resolved analysis of CAR-T cell induced apoptosis of low frequency target cells using an Image-enhanced flow cytometer was enabled by fluorescent protein compensation with BrightComp eBeads
Jayanth S
Narayanan
,
Erin
Taylor
Journal for ImmunoTherapy of Cancer
Nov 2023,
11
(Suppl 1)
A332;
DOI:
10.1136/jitc-2023-SITC2023.0291
Pages
« first
‹ previous
…
192
193
194
195
196
197
198
199
200
…
next ›
last »
Special collections
COVID-19
(45)
Editor's choice
JITC
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Basic Tumor Immunology
(560)
Case Reports
(191)
Clinical Trials Monitor
(17)
Clinical/Translational Cancer Immunotherapy
(983)
Commentary/Editorials
(153)
Computational I-O
(4)
COVID-19 and Cancer Immunotherapy
(10)
Emerging Immunotherapeutic Agents
(5)
Guidelines and Consensus Statements
(56)
Guidelines and Consensus Statements
(53)
Imaging and Immunotherapy
(9)
Immune Cell Therapies and Immune Cell Engineering
(242)
Immune Checkpoints - Beyond PD-1
(8)
Immune Checkpoints Beyond PD-1 Series
(8)
Immune Monitoring Technology Primers
(12)
Immunotherapy Biomarkers
(437)
Liquid Biopsies
(10)
Microbial-Based Cancer Immunotherapy
(4)
Oncolytic and Local Immunotherapy
(151)
Reviews
(245)
The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer (SITC)
(1)
Open access
(5026)
Press releases
(2)
